Technical Analysis for APRE - Aprea Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 4.77 | 3.54% | 0.16 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 3.54% | |
| Below Lower BB | Weakness | 3.54% | |
| Down 3 Days in a Row | Weakness | 3.54% | |
| Lower Bollinger Band Touch | Weakness | 3.54% | |
| Oversold Stochastic | Weakness | 3.54% |
| Alert | Time |
|---|---|
| Gap Up Closed | 1 day ago |
| Gap Up Partially Closed | 1 day ago |
| Reversed from Up | 1 day ago |
| Gapped Up (Partial) | 1 day ago |
| Rose Above Lower Bollinger Band | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.78 |
| Average Volume | 9,979 |
| 200-Day Moving Average | 5.02 |
| 50-Day Moving Average | 5.60 |
| 20-Day Moving Average | 5.26 |
| 10-Day Moving Average | 5.02 |
| Average True Range | 0.35 |
| RSI (14) | 38.65 |
| ADX | 22.27 |
| +DI | 12.96 |
| -DI | 26.31 |
| Chandelier Exit (Long, 3 ATRs) | 4.86 |
| Chandelier Exit (Short, 3 ATRs) | 5.54 |
| Upper Bollinger Bands | 5.93 |
| Lower Bollinger Band | 4.58 |
| Percent B (%b) | 0.14 |
| BandWidth | 25.66 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.17 |
| MACD Histogram | -0.0525 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.17 | ||||
| Resistance 3 (R3) | 5.13 | 4.95 | 5.11 | ||
| Resistance 2 (R2) | 4.95 | 4.85 | 4.97 | 5.08 | |
| Resistance 1 (R1) | 4.86 | 4.78 | 4.90 | 4.90 | 5.06 |
| Pivot Point | 4.68 | 4.68 | 4.70 | 4.70 | 4.68 |
| Support 1 (S1) | 4.59 | 4.58 | 4.64 | 4.64 | 4.48 |
| Support 2 (S2) | 4.41 | 4.51 | 4.43 | 4.46 | |
| Support 3 (S3) | 4.32 | 4.41 | 4.43 | ||
| Support 4 (S4) | 4.37 |
